(5-064) Analysis of a Cystic Fibrosis-Specific Antibiogram Before and After FDA Approval of Elexacaftor/Tezacaftor/Ivacaftor (ETI)

Monday, December 5, 2022

4:15 PM – 5:15 PM

Location: Bayside A, Level 1

Category: Evaluative Study
Topic: Pediatrics

Co-Author(s): Jane Beyer, Elizabeth Elson

Primary Author(s)

Kathryn E. Bohannan
Inpatient Clinical Pharmacy Intern at Children's Mercy Hospital
University of Missouri-Kansas City School of Pharmacy, Missouri